

Joint Working

Executive Summary

Project title

AF Quality Audit

Project partners

Health Innovation Network (HIN) AHSN (on behalf of Southwark CCG) and Daiichi Sankyo UK Ltd

Start date

September 2019

Project summary

Anticoagulation in clinical practice has undergone a transformation since the introduction of the direct oral anticoagulants (DOACs). Until then the primary option for treatment was warfarin and patients were under the long-term care of anticoagulant specialists. Now anticoagulation therapy can be initiated and monitored by a range of clinicians across primary care (GPs, nurses, pharmacists) and secondary care (cardiology, stroke, care of the elderly, general medicine). Whilst this change in practice has improved access to anticoagulation, there are concerns regarding the quality and safety of prescribing practice particularly choice of drug, dose prescribed and the monitoring undertaken. This project seeks to undertake an audit of DOAC prescribing in primary care to assess whether local prescribing practice is safe and effective.

Expected benefits to patients, the NHS and Daiichi-Sankyo

This project provides the assurance that the prescribing of DOACs in Southwark CCG is safe and effective. Also to develop the evidence of the quality and safety of prescribing of DOACs and a systematic process to maintain the safe and effective prescribing of DOACs.

The benefit of this project for Daiichi-Sankyo is increase in reputational profile, and the opportunity to work in partnership with the Health Innovation Network (HIN) AHSN, in which

the overall aim is to improve the health and well-being of patients with atrial fibrillation through improved management of the condition.

It is anticipated as part of the project that more patients may be treated with a pharmaceutical product. This may include but is not exclusive to products manufactured by Daiichi-Sankyo.